AbbVie logged a 0.5% change during today's afternoon session, and is now trading at a price of $148.93 per share. On average, analysts give it a target price of $169.92.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The large-cap company is based in the United States. AbbVie currently returns an annual dividend yield of 3.9%.
What to Consider if You Are Thinking of Buying AbbVie:
-
AbbVie has moved 10.0% over the last year.
-
ABBV has a forward P/E ratio of 13.5 based on its EPS guidance of 11.07.
-
Over the last 6 years, earnings per share (EPS) have been growing at a compounded average rate of 6.6%.
-
The company has a price to earnings growth (PEG) ratio of -3.01.
-
Its Price to Book (P/B) ratio is 20.43
AbbVie Has a Pattern of Improving Cash Flows
Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
---|---|---|---|---|
2023-02-17 | 24,943,000 | -695,000 | 25,638,000 | 8.8 |
2022-02-18 | 22,777,000 | -787,000 | 23,564,000 | 28.16 |
2021-02-19 | 17,588,000 | -798,000 | 18,386,000 | 32.5 |
2020-02-21 | 13,324,000 | -552,000 | 13,876,000 | -1.34 |
2019-02-27 | 13,427,000 | -638,000 | 14,065,000 | 34.09 |
2018-02-16 | 9,960,000 | -529,000 | 10,489,000 |
AbbVie's free cash flow history is impressive because it displays year-on-year increases over the last 6 years. Averaging out at $17.67 Billion, and following a compounded average growth rate of 0.0%, investors who focus on cash flow growth should do further research on this firm.